We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Vanda (VNDA) Falls on FDA's CRL to Hetlioz sNDA for Insomnia
Read MoreHide Full Article
Shares of Vanda Pharmaceuticals Inc. (VNDA - Free Report) were down 5.6% on Mar 6 after the company announced that the FDA issued a complete response letter (CRL) to a supplemental new drug application (sNDA) for its marketed product, Hetlioz (tasimelteon), on Mar 4.
The sBLA sought approval for Hetlioz for the treatment of insomnia, which is characterized by difficulties with sleep initiation.
The FDA notified the company that it had identified deficiencies that precluded discussion of labeling and post-marketing requirements/commitments related to the Hetlioz sNDA early last month. No deficiencies were disclosed by the FDA in the notification.
The regulatory body issued the CRL stating that it cannot approve the sNDA in its current form.
Shares of Vanda have plunged 36.9% in the past year compared with the industry’s decline of 3.7%.
Image Source: Zacks Investment Research
The company submitted the sNDA for Hetlioz in insomnia in May 2023. A decision from the FDA was expected on Mar 04, 2024.
Hetlioz is currently approved for the treatment of non-24-hour sleep-wake disorder and nighttime sleep disturbances in Smith-Magenis syndrome.
As Hetlioz is facing the risk of generic launches, the company is working to expand its label. However, the latest CRL to the sNDA for Hetlioz is likely to delay the approval and the expected launch of the drug for a new indication.
VNDA is also looking to pursue the FDA’s approval for Hetlioz in jet lag disorder.
Another approved product in Vanda’s commercial portfolio is Fanapt, which is approved for the treatment of schizophrenia.
A sNDA seeking approval for Fanapt for treating adult patients with bipolar I disorder is also under review, with a decision from the FDA expected on Apr 2, 2024.
Zacks Rank & Other Stocks to Consider
Vanda currently sports a Zacks Rank #1 (Strong Buy).
In the past 60 days, estimates for Indivior’s 2024 earnings per share have improved from $1.83 to $1.95. In the past year, shares of INDV have risen 4.2%.
Indivior’s earnings beat estimates in each of the trailing three quarters. INDV delivered an average earnings surprise of 48.06%.
In the past 60 days, estimates for ADMA Biologics’ 2024 earnings per share have improved from 18 cents to 30 cents. In the past year, shares of ADMA have increased 79.5%.
ADMA Biologics’ earnings beat estimates in three of the trailing four quarters and met the same once. ADMA delivered an average earnings surprise of 85.00%.
In the past 60 days, estimates for ANI Pharmaceuticals’ 2024 earnings per share have improved from $4.06 to $4.22. In the past year, shares of ANIP have risen 52.6%.
Earnings of ANI Pharmaceuticals beat estimates in each of the trailing four quarters. ANIP delivered a four-quarter average earnings surprise of 109.60%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Vanda (VNDA) Falls on FDA's CRL to Hetlioz sNDA for Insomnia
Shares of Vanda Pharmaceuticals Inc. (VNDA - Free Report) were down 5.6% on Mar 6 after the company announced that the FDA issued a complete response letter (CRL) to a supplemental new drug application (sNDA) for its marketed product, Hetlioz (tasimelteon), on Mar 4.
The sBLA sought approval for Hetlioz for the treatment of insomnia, which is characterized by difficulties with sleep initiation.
The FDA notified the company that it had identified deficiencies that precluded discussion of labeling and post-marketing requirements/commitments related to the Hetlioz sNDA early last month. No deficiencies were disclosed by the FDA in the notification.
The regulatory body issued the CRL stating that it cannot approve the sNDA in its current form.
Shares of Vanda have plunged 36.9% in the past year compared with the industry’s decline of 3.7%.
Image Source: Zacks Investment Research
The company submitted the sNDA for Hetlioz in insomnia in May 2023. A decision from the FDA was expected on Mar 04, 2024.
Hetlioz is currently approved for the treatment of non-24-hour sleep-wake disorder and nighttime sleep disturbances in Smith-Magenis syndrome.
As Hetlioz is facing the risk of generic launches, the company is working to expand its label. However, the latest CRL to the sNDA for Hetlioz is likely to delay the approval and the expected launch of the drug for a new indication.
VNDA is also looking to pursue the FDA’s approval for Hetlioz in jet lag disorder.
Another approved product in Vanda’s commercial portfolio is Fanapt, which is approved for the treatment of schizophrenia.
A sNDA seeking approval for Fanapt for treating adult patients with bipolar I disorder is also under review, with a decision from the FDA expected on Apr 2, 2024.
Zacks Rank & Other Stocks to Consider
Vanda currently sports a Zacks Rank #1 (Strong Buy).
Some other top-ranked stocks in the healthcare sector are Indivior PLC (INDV - Free Report) , ADMA Biologics, Inc. (ADMA - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) , each carrying a Zacks Rank #1 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Indivior’s 2024 earnings per share have improved from $1.83 to $1.95. In the past year, shares of INDV have risen 4.2%.
Indivior’s earnings beat estimates in each of the trailing three quarters. INDV delivered an average earnings surprise of 48.06%.
In the past 60 days, estimates for ADMA Biologics’ 2024 earnings per share have improved from 18 cents to 30 cents. In the past year, shares of ADMA have increased 79.5%.
ADMA Biologics’ earnings beat estimates in three of the trailing four quarters and met the same once. ADMA delivered an average earnings surprise of 85.00%.
In the past 60 days, estimates for ANI Pharmaceuticals’ 2024 earnings per share have improved from $4.06 to $4.22. In the past year, shares of ANIP have risen 52.6%.
Earnings of ANI Pharmaceuticals beat estimates in each of the trailing four quarters. ANIP delivered a four-quarter average earnings surprise of 109.60%.